0.9% sodium chloride injection (DrugBank: Sodium chloride, Chloride)
20 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 1 |
11 | Myasthenia | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
14 | Chronic inflammatory demyelinating polyneuropathy | 0 |
34 | Neurofibromatosis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
50 | Dermatomyositis | 0 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
60 | Aplastic anemia | 0 |
65 | Primary immunodeficiency | 0 |
78 | Hypopituitarism | 0 |
96 | Crohn disease | 0 |
168 | Ehlers-Danlos syndrome | 1 |
193 | Prader-Willi syndrome | 0 |
227 | Osler disease | 0 |
228 | Bronchiolitis obliterans | 0 |
271 | Ankylosing spondylitis | 0 |
288 | Autoimmune acquired coagulation factor deficiency [Autoimmune Hemorrhaphilia XIII (~Mar 2017)] | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-INR-17012013 | 2017-09-01 | 2017-07-17 | Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease | Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease | Parkinson‘s disease, Depression | BTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection; | Shanghai Tongji Hospital, Tongji University | NULL | Pending | 18 | 80 | Both | BTX-A:40;Placebo:40; | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04036305 (ClinicalTrials.gov) | July 26, 2019 | 25/7/2019 | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Ehlers-Danlos Syndrome;Anesthesia, Local | Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5% | Vanderbilt University Medical Center | University of Calgary | Enrolling by invitation | 18 Years | N/A | All | 230 | United States |